Advent in negotiations to acquire Sanofi’s generics business

Advent International and Sanofi have entered into exclusive negotiations under which Advent would acquire Zentiva, Sanofi’s European generics business for €1.9 billion.

The transaction is expected to close by the end of 2018, subject to finalisation of definitive agreements, completion of the appropriate social processes and approval of relevant regulatory authorities.

Olivier Brandicourt, Chief Executive Officer, Sanofi said, “Zentiva is a robust business with a highly talented workforce and we believe it has demonstrated its potential for growth. We have determined that transferring this business to Advent is the best option to ensure its long-term success.”